Detalhe da pesquisa
1.
Interrupting Endocrine Therapy to Attempt Pregnancy after Breast Cancer.
N Engl J Med
; 388(18): 1645-1656, 2023 May 04.
Artigo
Inglês
| MEDLINE | ID: mdl-37133584
2.
Clinical behavior of recurrent hormone receptor-positive breast cancer by adjuvant endocrine therapy within the Breast International Group 1-98 clinical trial.
Cancer
; 127(5): 700-708, 2021 03 01.
Artigo
Inglês
| MEDLINE | ID: mdl-33290610
3.
Tailoring Adjuvant Endocrine Therapy for Premenopausal Breast Cancer.
N Engl J Med
; 379(2): 122-137, 2018 Jul 12.
Artigo
Inglês
| MEDLINE | ID: mdl-29863451
4.
Cumulative incidence of cardiovascular events under tamoxifen and letrozole alone and in sequence: a report from the BIG 1-98 trial.
Breast Cancer Res Treat
; 185(3): 697-707, 2021 Feb.
Artigo
Inglês
| MEDLINE | ID: mdl-33159633
5.
Correction: Quality of life under extended continuous versus intermittent adjuvant letrozole in lymph node-positive, early breast cancer patients: the SOLE randomised phase 3 trial.
Br J Cancer
; 122(7): 1119, 2020 Mar.
Artigo
Inglês
| MEDLINE | ID: mdl-31949268
6.
Treatment-induced symptoms, depression and age as predictors of sexual problems in premenopausal women with early breast cancer receiving adjuvant endocrine therapy.
Breast Cancer Res Treat
; 181(2): 347-359, 2020 Jun.
Artigo
Inglês
| MEDLINE | ID: mdl-32274665
7.
Endocrine-responsive lobular carcinoma of the breast: features associated with risk of late distant recurrence.
Breast Cancer Res
; 21(1): 153, 2019 12 30.
Artigo
Inglês
| MEDLINE | ID: mdl-31888717
8.
Quality of life under extended continuous versus intermittent adjuvant letrozole in lymph node-positive, early breast cancer patients: the SOLE randomised phase 3 trial.
Br J Cancer
; 120(10): 959-967, 2019 05.
Artigo
Inglês
| MEDLINE | ID: mdl-30967649
9.
Long-term responders to trastuzumab monotherapy in first-line HER-2+ advanced breast cancer: characteristics and survival data.
BMC Cancer
; 19(1): 902, 2019 Sep 10.
Artigo
Inglês
| MEDLINE | ID: mdl-31500588
10.
Cancer immunotherapy efficacy and patients' sex: a systematic review and meta-analysis.
Lancet Oncol
; 19(6): 737-746, 2018 06.
Artigo
Inglês
| MEDLINE | ID: mdl-29778737
11.
Axillary dissection versus no axillary dissection in patients with breast cancer and sentinel-node micrometastases (IBCSG 23-01): 10-year follow-up of a randomised, controlled phase 3 trial.
Lancet Oncol
; 19(10): 1385-1393, 2018 10.
Artigo
Inglês
| MEDLINE | ID: mdl-30196031
12.
Extended adjuvant intermittent letrozole versus continuous letrozole in postmenopausal women with breast cancer (SOLE): a multicentre, open-label, randomised, phase 3 trial.
Lancet Oncol
; 19(1): 127-138, 2018 01.
Artigo
Inglês
| MEDLINE | ID: mdl-29158011
13.
11 years' follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin Adjuvant (HERA) trial.
Lancet
; 389(10075): 1195-1205, 2017 03 25.
Artigo
Inglês
| MEDLINE | ID: mdl-28215665
14.
Adjuvant ovarian suppression in premenopausal breast cancer.
N Engl J Med
; 372(5): 436-46, 2015 Jan 29.
Artigo
Inglês
| MEDLINE | ID: mdl-25495490
15.
Mutational analysis of triple-negative breast cancers within the International Breast Cancer Study Group (IBCSG) Trial 22-00.
Breast Cancer Res Treat
; 170(2): 351-360, 2018 Jul.
Artigo
Inglês
| MEDLINE | ID: mdl-29589138
16.
Adjuvant exemestane with ovarian suppression in premenopausal breast cancer.
N Engl J Med
; 371(2): 107-18, 2014 Jul 10.
Artigo
Inglês
| MEDLINE | ID: mdl-24881463
17.
Impact of CYP19A1 and ESR1 variants on early-onset side effects during combined endocrine therapy in the TEXT trial.
Breast Cancer Res
; 18(1): 110, 2016 11 08.
Artigo
Inglês
| MEDLINE | ID: mdl-27825388
18.
Time to incorporate germline multigene panel testing into breast and ovarian cancer patient care.
Breast Cancer Res Treat
; 160(3): 393-410, 2016 12.
Artigo
Inglês
| MEDLINE | ID: mdl-27734215
19.
Tumor-infiltrating lymphocytes (TILs) are a powerful prognostic marker in patients with triple-negative breast cancer enrolled in the IBCSG phase III randomized clinical trial 22-00.
Breast Cancer Res Treat
; 158(2): 323-31, 2016 07.
Artigo
Inglês
| MEDLINE | ID: mdl-27372069
20.
Trastuzumab re-treatment following adjuvant trastuzumab and the importance of distant disease-free interval: the HERA trial experience.
Breast Cancer Res Treat
; 155(1): 127-32, 2016 Jan.
Artigo
Inglês
| MEDLINE | ID: mdl-26708471